Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

Heejoon Jang

A decade of liver organoids: Advances in disease modeling

Yue Liu

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity

Hong-Kyu Kim

The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review

Young-Joo Jin

Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes

Hydar El Jamaly

History and future of hepatitis B virus control in South Korea

Do Young Kim

Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights

Kenichi Ikejima

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

Hyun Young Woo

Carnitine palmitoyl transferase 1A deficiency in an adult with recurrent severe steato hepatitis aggravated by high pathologic or physiologic demands: A roller-coaster for internists

Prasit Phowthongkum

Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt

Dongmei Zhao

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

David Sooik Kim

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

Christian Mölleken

KASL clinical practice guidelines for management of chronic hepatitis B

Advances in ultrasound diagnosis in chronic liver diseases

Hitoshi Maruyama

Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?

Elham Ahmed Hassan

Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend

Grace Lai-Hung Wong

Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?

Jong Eun Yeon

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?

Do Young Kim

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE

Jung Hee Kim

Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion

Jihyun An

A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function

Hyun Yang

Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B

Kwan Sik Lee

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs

Stephen Caldwell

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection

Hee Chul Nam

Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy

Soon Jae Lee

Percutaneous cryoablation for hepatocellular carcinoma

Kyoung Doo Song

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B

Han Ah Lee

Intraductal malignant tumors in the liver mimicking cholangiocarcinoma: Imaging features for differential diagnosis

Ah Yeong Kim